A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer

PURPOSE: Anlotinib is a newly developed oral multitarget tyrosine kinase inhibitor. We retrospectively evaluated the toxicity and clinical efficacy of chemotherapy combined with anlotinib versus chemotherapy alone for metastatic/advanced non-small cell lung cancer (NSCLC) in patients who failed firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hai-ying, Chu, Jun-feng, Zhao, Yan, Tang, Hong, Wang, Li-li, Zhou, Meng-qiang, Yan, Zheng, Liu, Yan-yan, Yao, Zhi-hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250176/
https://www.ncbi.nlm.nih.gov/pubmed/32547218
http://dx.doi.org/10.2147/CMAR.S249678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250176/
https://www.ncbi.nlm.nih.gov/pubmed/32547218
http://dx.doi.org/10.2147/CMAR.S249678

Ejemplares similares